Evidence map›Paper›PMID 35511152›Full record

ArticleInternational journal of radiation biology2023

Low-dose radiotherapy for COVID-19 pneumonia and cancer: summary of a recent symposium and future perspectives.

Mark P Little, Wei Zhang, Roy van Dusen, Nobuyuki Hamada, Michelle Bugden, Meiyun Cao, Kiersten Thomas, Deyang Li, Yi Wang, Megha Chandrashekhar and 2 more

Open access · greenAbstract read
In one paragraph

Article in International journal of radiation biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Radiotherapy for non-cancer diseases: benefits and long-term risks.International journal of radiation biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 4 countries.

Mark P LittleRadiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Rockville, MD, USA.ORCID 0000-0003-0980-7567
Wei ZhangRadiation Effects Department, UK Health Security Agency (UKHSA), Chilton, UK.ORCID 0000-0002-6508-364X
Roy van DusenInformation Management Services, Silver Spring, MD, USA.
Nobuyuki HamadaBiology and Environmental Chemistry Division, Sustainable System Research Laboratory, Central Research Institute of Electric Power Industry (CRIEPI), Komae, Japan.ORCID 0000-0003-2518-6131
Michelle BugdenRadiobiology and Health Branch, Canadian Nuclear Laboratories, Chalk River, Canada.
Meiyun CaoRadiobiology and Health Branch, Canadian Nuclear Laboratories, Chalk River, Canada.
Kiersten ThomasRadiobiology and Health Branch, Canadian Nuclear Laboratories, Chalk River, Canada.
Deyang LiRadiobiology and Health Branch, Canadian Nuclear Laboratories, Chalk River, Canada.
Yi WangRadiobiology and Health Branch, Canadian Nuclear Laboratories, Chalk River, Canada.
Megha ChandrashekharRadiobiology and Health Branch, Canadian Nuclear Laboratories, Chalk River, Canada.
Mohammad K KhanDepartment of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
C Norman ColemanRadiation Research Program, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, DHHS, Rockville, MD, USA.
Canadian Nuclear Laboratories · CAUnited States Department of Health and Human Services · USCentral Research Institute of Electric Power Industry · JPEmory University · USInformation Management Services · USUK Health Security Agency · GBUniversity of Ottawa · CA

Funding

Studies of Populations Exposed to Therapeutic Medical Radiation and Other AgentsZIACP010131 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MORTON, LINDSAY · 2009 to 2025
$81.0M
Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

The lessons learned from the Coronavirus Disease 2019 (COVID-19) pandemic are numerous. Low dose radiotherapy (LDRT) was used in the pre-antibiotic era as treatment for bacterially/virally associated pneumonia. Motivated in part by these historic clinical and radiobiological data, LDRT for treatment of COVID-19-associated pneumonia was proposed in early 2020. Although there is a large body of epidemiological and experimental data pointing to effects such as cancer at low doses, there is some evidence of beneficial health effects at low doses. It has been hypothesized that low dose radiation could be combined with immune checkpoint therapy to treat cancer. We shall review here some of these old radiobiological and epidemiological data, as well as the newer data on low dose radiation and stimulated immune response and other relevant emerging data. The paper includes a summary of several oral presentations given in a Symposium on "Low dose RT for COVID and other inflammatory diseases" as part of the 67th Annual Meeting of the Radiation Research Society, held virtually 3-6 October 2021.

Indexed as

COVID-19NeoplasmsHumansRadiotherapyRadiotherapy Dosagecancer riskCOVID-19epidemiologyLow dose radiotherapyradiobiology

Identifiers

PMID35511152
PMCPMC11270648
OpenAlexW4229018424

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.